Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Precision medicine aims for individualized treatment via patient genotyping and targeted therapies.
• Non-small cell lung cancer (NSCLC) has well-studied pathogenic genes, making genotype-based targeted therapy highly successful.
• Genotyping and targeted therapy represent a significant advancement in personalized cancer care.

Purpose of the Study:

• To focus on precision treatment strategies for non-small cell lung cancer (NSCLC) based on patient genotyping.
• To compare various gene detection methods applicable to NSCLC.
• To summarize recent advancements in NSCLC immunotherapy.

Main Methods:

• Literature review of precision medicine in NSCLC.
• Comparative analysis of gene detection techniques (e.g., PCR, NGS).
• Synthesis of current research on NSCLC targeted therapies and immunotherapies.

Main Results:

• Genotyping is crucial for identifying actionable mutations in NSCLC.
• Multiple gene detection methods offer varying sensitivity, specificity, and cost-effectiveness.
• NSCLC immunotherapy, particularly immune checkpoint inhibitors, has shown significant clinical efficacy.

Conclusions:

• Genotype-guided targeted therapy is a cornerstone of precision medicine for NSCLC.
• The choice of gene detection method impacts treatment decisions.
• Advances in NSCLC immunotherapy offer new hope for patients, often in combination with targeted treatments.